China Cell Therapy Party On: $500m+ Raised In JW IPO, Other Rounds

CAR-T Developer Plans US, Europe Expansion

It's been a big week for cell therapy developers in China with well over $500m raised through an IPO and large new funding rounds for several other ventures.

DIA panel on CAR-T in China, held in Suzhou Oct. 26, 2018
WUXI APPTEC COO STEVE YANG (FAR RIGHT) AND FOSUN-KITE CEO RICHARD WANG (FIRST LEFT) AT THE DIA CHINA MEETING IN 2018 • Source: Courtesy of DIA

Ahead of what may be China’s first regulatory approval for a cell therapy, the Chinese joint venture between Juno Therapeutics Inc. and WuXi AppTec Inc., JW Therapeutics Co., Ltd, has listed on the Hong Kong Stock Exchange in the latest initial public offering involving a biotech from the mainland.

Shanghai-based JW raised HKD2.33bn ($300m) via the IPO. which the company will use in part to progress several cell therapies...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

More from Advanced Therapies